Cargando…

Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China

Chronic liver disease and liver cancer associated with chronic hepatitis B (CHB) are leading causes of death among adults in China. Although newborn hepatitis B immunization has successfully reduced the prevalence of CHB in children, about 100 million Chinese adults remain chronically infected. If l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toy, Mehlika, Hutton, David W., So, Samuel K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633043/ https://www.ncbi.nlm.nih.gov/pubmed/26536626 http://dx.doi.org/10.1371/journal.pone.0139876

Ejemplares similares

Costs and health impact of delayed implementation of a national hepatitis B treatment program in China
por: Toy, Mehlika, et al.
Publicado: (2022)

Cost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections
por: Hutton, David W., et al.
Publicado: (2022)

North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
por: Malvankar-Mehta, Monali S, et al.
Publicado: (2019)

Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan
por: Karasawa, Yusuke, et al.
Publicado: (2021)

Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income
por: Tordrup, David, et al.
Publicado: (2020)

U.S. cannabis laws projected to cost generic and brand pharmaceutical firms billions
por: Bednarek, Ziemowit, et al.
Publicado: (2022)

Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study
por: George, Thomas, et al.
Publicado: (2021)

Gaps and Disparities in Chronic Hepatitis B Monitoring and Treatment in the United States, 2016-2019
por: Pham, Thi T. Hang, et al.
Publicado: (2023)

Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
por: Desai, Rishi J, et al.
Publicado: (2018)

Safety and efficacy of generic drugs with respect to brand formulation
por: Gallelli, Luca, et al.
Publicado: (2013)

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Brand and generic medications: Are they interchangeable?
por: Al-Jazairi, Abdulrazaq S., et al.
Publicado: (2008)

Prescription writing: Generic or brand?
por: Andrade, Chittaranjan, et al.
Publicado: (2017)

Brand Name Versus Generic?
por: Aungaroon, Gewalin
Publicado: (2023)

The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country
por: Toy, Mehlika, et al.
Publicado: (2012)

The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs
por: Thakkar, Karan B., et al.
Publicado: (2013)

Prescription Drug Costs and the Generic Dispensing Ratio
por: Liberman, Joshua N., et al.
Publicado: (2010)

Generic versus brand-name drugs used in cardiovascular diseases
por: Manzoli, Lamberto, et al.
Publicado: (2015)

Generics versus brand-named drugs for glaucoma: the debate continues
por: Bhartiya, Shibal, et al.
Publicado: (2020)

Pharmacist Intervention in Safe and Effective Conversion of Brand to Generic Drugs
por: Summers, Kent H.
Publicado: (2005)

The Prevalence and Predictors of Low-Cost Generic Program Use in a Nationally Representative Uninsured Population
por: Brown, Joshua D., et al.
Publicado: (2016)

Generic Drug Cost Containment in Medicaid: Lessons from Five State MAC Programs
por: Abramson, Richard G., et al.
Publicado: (2004)

Regulatory Solutions to the Problem of High Generic Drug Costs
por: Luo, Jing, et al.
Publicado: (2015)

Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Elemental impurities analysis in name-brand and generic omeprazole drug samples
por: Pinheiro, Fernanda C., et al.
Publicado: (2020)

Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults
por: Pauly, Nathan James, et al.
Publicado: (2015)

Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States
por: Wang, Ching‐Yu, et al.
Publicado: (2020)

Brands, costs and registration status of antimalarial drugs in the Kenyan retail sector
por: Amin, Abdinasir A, et al.
Publicado: (2005)

Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C
por: Heath, Katherine
Publicado: (2018)

The Prevalence and Predictors of Low-Cost Generic Program Use in the Pediatric Population
por: Pauly, Nathan James, et al.
Publicado: (2015)

Discontinuation Rates and Health Care Costs in Adult Patients Starting Generic Versus Brand SSRI or SNRI Antidepressants in Commercial Health Plans
por: Kautzner, Adam, et al.
Publicado: (2011)

CostPlus and implications for generic imatinib
por: Jenei, Kristina, et al.
Publicado: (2022)

Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B
por: Hsu, Po-Ke, et al.
Publicado: (2022)

Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
por: Wadhwani, Meenakshi, et al.
Publicado: (2016)

Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California
por: Toy, Mehlika, et al.
Publicado: (2018)

Impact of Generic Alendronate Cost on the Cost-Effectiveness of Osteoporosis Screening and Treatment
por: Nayak, Smita, et al.
Publicado: (2012)

Effects of Medicare Part D coverage gap closure on utilization of branded and generic drugs
por: Liu, Judith, et al.
Publicado: (2022)

Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China
por: Huang, Tao, et al.
Publicado: (2022)

Evaluation of blood pressure lowering effect by generic and brand-name antihypertensive drugs treatment: a multicenter prospective study in China
por: Zhang, Shu-Yuan, et al.
Publicado: (2021)

Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs
por: Rome, Benjamin N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ht8m5o8nc67lfuv6h29931qon